Annual Financials for Corbus Pharmaceuticals Holdings Inc.
Fiscal year is January-December. All values USD millions. |
2015 | 2016 | 2017 | 2018 | 2019 |
5-year trend |
Sales/Revenue
|
648,382 | 1.91M | 2.44M | 4.82M | 36.14M | |
Sales Growth |
- | 194.80% | 27.66% | 97.62% | 649.51% | |
Cost of Goods Sold (COGS) incl. D&A |
- | - | - | - | - | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
43,943 | 87,664 | 255,652 | 493,938 | 1.23M | |
Depreciation |
43,943 | 87,664 | 255,652 | 493,938 | 1.23M | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | - | - | - | - | |
Gross Income |
- | - | - | - | - | |
Gross Income Growth |
- | - | - | - | - | |
Gross Profit Margin |
- | - | - | - | - | NA |
|
2015 | 2016 | 2017 | 2018 | 2019 |
5-year trend |
SG&A Expense |
9.46M | 21.81M | 34.75M | 61.08M | 116.6M | |
Research & Development |
5.89M | 15.44M | 26.04M | 48.61M | 94.19M | |
Other SG&A |
3.57M | 6.37M | 8.71M | 12.46M | 22.41M | |
SGA Growth |
- | 130.58% | 59.33% | 75.77% | 90.91% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | - | 191,244 | - | |
EBIT after Unusual Expense |
- | - | - | (56.94M) | - | |
Non Operating Income/Expense |
1,980 | (14,090) | (41,910) | 284,040 | 4.42M | |
Non-Operating Interest Income |
3,417 | 4,878 | 196,487 | 990,208 | 1.25M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
2,440 | 4,401 | 13,375 | 7,431 | 19,025 | |
Interest Expense Growth |
- | 80.37% | 203.91% | -44.44% | 156.02% | |
Gross Interest Expense |
2,440 | 4,401 | 13,375 | 7,431 | 19,025 | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(8.85M) | (20M) | (32.42M) | (55.67M) | (76.04M) | |
Pretax Income Growth |
- | -125.95% | -62.12% | -71.71% | -36.58% | |
Pretax Margin |
- | - | - | - | -210.37% | NA |
Income Tax |
- | - | - | - | (4.58M) | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | 4.58M | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(8.85M) | (20M) | (32.42M) | (55.67M) | (71.45M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(8.85M) | (20M) | (32.42M) | (55.67M) | (71.45M) | |
Net Income Growth |
- | -125.95% | -62.12% | -71.71% | -28.35% | |
Net Margin Growth |
- | - | - | - | -197.69% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(8.85M) | (20M) | (32.42M) | (55.67M) | (71.45M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(8.85M) | (20M) | (32.42M) | (55.67M) | (71.45M) | |
EPS (Basic) |
(0.28) | (0.49) | (0.65) | (0.98) | (1.12) | |
EPS (Basic) Growth |
- | -75.00% | -32.65% | -50.26% | -14.49% | |
Basic Shares Outstanding |
31.35M | 41.14M | 50.18M | 57M | 63.9M | |
EPS (Diluted) |
(0.28) | (0.49) | (0.65) | (0.98) | (1.12) | |
EPS (Diluted) Growth |
- | -75.00% | -32.65% | -50.26% | -14.49% | |
Diluted Shares Outstanding |
31.35M | 41.14M | 50.18M | 57M | 63.9M | |
EBITDA |
(8.81M) | (19.9M) | (32.31M) | (56.25M) | (80.46M) | |
EBITDA Growth |
- | -125.86% | -62.37% | -74.12% | -43.02% | |
EBITDA Margin |
- | - | - | - | -222.60% | NA |